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Abstract
The tests currently employed within most haemostasis laboratories to monitor anticoagulant therapy largely comprise the prothrombin time (PT)/
International Normalised Ratio (INR) and the activated partial thromboplastin time (APTT). These are respectively used to monitor Vitamin K antag-
onists (VKAs) such as warfarin, and unfractionated heparin. Additional tests that laboratories may also employ for assessing or monitoring unfrac-
tionated heparin include thrombin time (TT) and the anti-Xa assay, which can also be used to monitor low molecular weight heparin. Several new 
anti-thrombotic agents have recently emerged, or are in the final process of clinical evaluation. These novel drugs that include Dabigatran etexilate 
and Rivaroxaban would not theoretically require monitoring; however, testing is useful in specific situations. The tests currently used to monitor 
VKAs and heparin are typically either too sensitive or too insensitive to the new drugs to be used as ‘typically performed in laboratories’, and may 
thus require some methodological adjustments to increase or decrease their sensitivity. Alternately, different tests may be better employed in these 
assessments. Whatever the case, laboratories may soon be performing a reduced or possibly increased number of tests, the same kind of tests but 
perhaps differently, or conceivably different assay panels. Specific laboratory guidance on the choice of the appropriate test to be ordered according 
to the drug being administered, as well as on appropriate interpretation of test results, will also be necessary. The current report reviews the current 
state of play and provides a glimpse to the possible future of the coagulation laboratory.
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Anticoagulant therapy monitoring represents the 
main purpose of most routine coagulation labora-
tories, along with preoperative screening . Antico-
agulants are alternatively referred to as ’anti-
thrombotics’, given their intended clinical thera-
peutic efficacy . The main current anticoagulant ar-
mamentarium comprises heparin and vitamin K 
antagonists (VKAs) (also known as coumarins) such 
as warfarin or acenocoumarol . The main new anti-
coagulant agents include, but do not exclusively 
comprise, Dabigatran etexilate, Rivaroxaban and 
Apixaban . VKAs and heparin are typically moni-
tored because they exhibit a narrow therapeutic 
window, and largely unpredictable behavior in 
treated individuals . In contrast, the newer agents 
have been clinically developed and evaluated as 
requiring little to null laboratory monitoring . Lab-
oratory testing of these agents will, however, be 
required in select cases, and laboratories should 
become proactive in recognizing the in-vitro be-
havior of these agents, developing appropriate 
strategies for any required testing, as well as es-
tablishing appropriate policies for post-test coun-
seling on test results and expected outcomes . 
Haemostasis, thrombosis and anticoagulant/
antithrombotic therapy
Haemostasis represents the mechanism whereby 
the body maintains circulatory flow . It can be rep-
resented by Vichow’s triad or - more commonly - 
as a balance of procoagulant and anticoagulant 
mechanisms or pathways, inclusive of fibrinolysis 
(1,2) . We have recently reviewed this in the context 
of the changing landscape of coagulation testing 
(3), and so shall only briefly reiterate the main as-
pects here . In brief, an injury to the vascular en-
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The reason that these two tests are used to re-
spectively monitor VKAs and UF relate to linear 
sensitivity over the therapeutic interval (Table 1) . 
The Quick PT/INR is sensitive to the presence and 
activity of FII (prothrombin), FV, FVII, FX and fi-
brinogen (FI) (Figure 1) . Thus, anticoagulant 
agents that affect the activity and/or level of 
these factors can influence this PT/INR, and by in-
ference, the PT/INR can be used to monitor these 
agents if a dose response relationship can be es-
tablished . The APTT is sensitive to the presence 
and activities of FII, FV, FVIII, FIX, FX, FXI, FXII and 
fibrinogen (FI) (Figure 1) . Analogous to the PT/
INR, any anticoagulant agent that affects the ac-
tivity and/or level of these factors can influence 
the APTT, and in turn, the APTT can be used to 
monitor these agents if a dose response relation-
ship can be established . In practice, the PT/INR 
shows good linear sensitivity to VKAs over the 
therapeutic range, and the APTT shows linear 
sensitivity to UH over the conventional thera-
peutic range . In contrast, the PT/INR is less sensi-
tive to UH, and is actively made insensitive by 
addition of heparin neutralizers (e .g ., heparinase 
or protamine), so that changes in the PT/INR dur-
ing the transition of patients from UH to VKA 
therapy reflects the latter’s effects only . Similarly, 
the APTT is less sensitive to VKAs than the PT/
INR .
These two basic coagulation tests are typically 
supplemented in many laboratories by fibrinogen 
assays, D-dimer tests, and occasionally thrombin 
time (TT) assays (Figure 1) . Together, these five as-
says may be used to assess the haemostasis sta-
tus in patients, including the potential for dissem-
inated intravascular coagulation (9), as well in dif-
ferential diagnosis strategies, or to assess for po-
tential preanalytical issues (10) . For example, the 
TT is very sensitive to UH (Figure 2), whereas fi-
brinogen assays tend to be less sensitive or are in-
sensitive . Thus, the TT and fibrinogen testing may 
play a role in evaluating for a differential diagno-
sis of fibrinogen deficiency or heparin excess, 
which may be important in assessing for inappro-
priate sample collection, sample clotting or hepa-
rin contamination . Otherwise, the TT, fibrinogen 
and D-dimer tests do not normally play a big part 
dothelium will initiate two major integrated ‘pro-
coagulant’ pathways, termed primary and second-
ary haemostasis, which will lead to eventual plug 
formation to prevent excessive hemorrhage . The 
primary pathway involves activation of platelets, 
the recruitment of von Willebrand factor (VWF) to 
promote platelet attachment to the site of injury, 
and the engagement of secondary haemostasis 
through various procoagulant proteins including 
fibrinogen, and coagulation factors (F) V and VIII 
(1-3) . Secondary haemostasis is also initiated di-
rectly by damage to the vasculature, primarily via 
the tissue factor pathway involving FVII, but also 
via the contact pathway, and as amplified by the 
primary pathway . In vitro, the tissue factor path-
way and the contact pathway are respectively mir-
rored by the prothrombin time (PT) and activated 
partial thromboplastin time (APTT) (Figure 1) . 
Various natural anticoagulants (e .g ., protein C 
[PC], protein S [PS], antithrombin [AT]) act to mod-
erate the secondary haemostasis pathway and 
prevent excessive procoagulant activity that may 
lead to thrombosis or vascular occlusion (2,4) . 
Thrombosis essentially represents a failure of the 
haemostatic balance, towards a state of ‘procoag-
ulation’ (i .e ., representing a comparative domi-
nance of procoagulant mechanisms or a failure of 
natural anticoagulant mechanisms to effectively 
temper the procoagulant pathway) (2-5) . Second-
ary haemostasis dysfunction leading to venous 
thrombosis is typically managed by anticoagulant 
therapy, classically comprising unfractionated 
heparin (UH) or low molecular weight heparin 
(LMWH), and VKAs . 
Coagulation tests used to routinely monitor 
anticoagulant therapy
For most haemostasis laboratories, the large bulk 
of routine coagulation tests performed comprise 
the PT/International Normalised Ratio (INR) for 
monitoring of VKAs, and within a hospital setting, 
the APTT for monitoring UH (2,3,6-8) . The INR rep-
resents a simple calculation as follows: 
INR = (patient PT/MNPT)ISI,
where the MNPT = mean normal PT, and ISI = in-
ternational sensitivity index . 
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in anticoagulant testing or antithrombotic thera-
py, except when the latter is used to assist deci-
sions on the duration of anticoagulant therapy in 
patients with recent episodes of venous throm-
bosis .
Non-routine ‘anticoagulant monitoring’ tests
A small selection of additional tests are sometimes 
used to assess the anticoagulant status of patients 
undergoing anticoagulant therapy (3) . The most 
commonly applied is the chromogenic anti-Xa as-
say (Figure 2), which is sensitive to the presence of 
UH, but which is most typically utilized - as re-
quired - to monitor LMWH (11) . 
Anticoagulant therapy – the classical approach
The post-thrombotic therapy is typically initiated 
using UH, since this agent exerts an immediate an-
ticoagulant effect (3) . UH provides a varied clinical 
responsiveness in different people, only in part re-
lated to body mass index and adiposity, and hence 
requires monitoring to ensure that a sufficient an-
ticoagulant effect is maintained, as well as to pre-
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Figure 1. A simplified representation of the classical secondary pathway of coagulation as represented by the common in-vitro co-
agulation tests, namely the prothrombin time (PT), the activated partial thromboplastin time (APTT) and the thrombin time (TT) . 
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that may lead to undesired bleeding . The narrow 
therapeutic window of anticoagulant effect is typi-
cally reflected by an APTT range of around 1 .5-2 .5x 
baseline values (11) . UH is administered parenter-
ally (i .e ., intravenous sodium heparin), and al-
though this is ‘acceptable’ for short-term hospital 
stays, it is uncomfortable for the patient . Other 
complications of UH therapy include the rare but 
potentially life-threatening condition known as 
heparin induced thrombocytopenia (HIT), which 
can also be associated with massive and life-
threatening thrombosis (HITT) (12-15) . 
Patients suffering thrombosis are thereby switched 
from UH to VKAs for long-term management . The 
normal post-thrombosis therapy lasts approxi-
mately 3-6 months, but in some cases can be ex-
tended (e .g ., AT deficiency, or composite of identi-
fied risk factors) or indefinite (e .g . antiphospholip-
id syndrome (APS), atrial fibrillation (AF), prosthetic 
heart valves) (16,17) . VKAs are not immediate act-
ing, taking several days to initiate effective antico-
agulation (3) . The dose-response is variable for 
several known and some unknown reasons, in-
cluding compliance, pharmacogenetics, drug and 
food interactions (18,19) . VKAs are also character-
ized by a narrow therapeutic window, typically re-
flected by an INR around 2 .0-3 .0 or 2 .5-3 .5, de-
pending on the clinical indication . The risk of 
bleeding might be worse than that with UH since 
the only effective therapeutic management is fac-
tor replacement therapy or administration of by-
passing agents such as recombinant activated FVII 
or anti-inhibitor coagulant complex (20) .
There is also the complicated issue of bridging 
from one agent (UH) to the other (VKAs), which re-
quires additional clinical care and monitoring at 
this time . There are also clinical and laboratory 
costs associated with monitoring and testing . 
Moreover, there is much inter-laboratory variation 
in laboratory test practice and test results (7,11,21), 
and variation also exists in terms of anticoagulant 
sensitivity for different PT and APTT reagents, thus 
casting some doubt on the actual clinical utility of 
some of the derived laboratory test results . 
More recently, the use of UH is being significantly 
reduced and in some cases abandoned in several 
countries, because LMWH has taken its place also 
in the initial phase of venous thromboembolism 
(VTE) treatment . This later pharmacological agents 
consist of chains of polysaccharides obtained with 
different approach to fractionation or depolymeri-
sation of polymeric heparin, which exhibit an aver-
age molecular weight of less than 8 kDa and con-
taining not less than 60% of chains with molecular 
weight lower than 8 kDa . LMWH provides some 
theoretical advantages over UH in terms of re-
duced need to monitor, and lower risk of compli-
cations such as HIT (11-15) . LMWH is administered 
by subcutaneous injection, but different commer-
cial products may differ substantially (22), and lab-
oratory monitoring, if performed, is still plagued 
by substantial inter-laboratory variation (23) .
New anticoagulants
The new and emerging oral anticoagulants are pri-
marily direct inhibitors of either factor Xa or 
thrombin (FIIa) . These agents do not (in theory) re-
quire laboratory monitoring, since they have been 
largely developed and clinically investigated with-
out laboratory testing (3,24-28) . The two agents 
most advanced in terms of global release and cur-
rently licensed clinical use are Dabigatran etexilate 
and Rivaroxaban, respectively reflecting anti-IIa 
and anti-Xa agents . Another agent in an advanced 
stage is Apixaban, another anti-Xa agent . As with 
the development of most new anticoagulants, ini-
tial evaluation and clearance for clinical use tends 
to be in well-defined at-risk groups such as prima-
ry prophylaxis for VTE prevention in orthopaedic 
surgery, followed by medical applications of post 
VTE treatment and secondary prevention, and the 
‘holy grail’ of anticoagulant drug treatment, name-
ly AF and prevention of stroke or systemic throm-
bosis . Stroke prevention in AF is the underlying in-
dication for approximately 50% of all patients 
treated with VKAs, and is thus a major target of the 
new anticoagulants, which is therefore expected 
to reflect the clinical indication that will mostly af-
fect the role and organization of anticoagulant 
centers worldwide . Current approved indications 
for Dabigatran etexilate and Rivaroxaban are simi-
lar, and based on extensive trials showing either 
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Figure 2. Control points for classical anticoagulants, and representation of monitoring by routine coagulation assays . 
A . Control points for vitamin K antagonists (VKAs) are factors (F) II, VII, IX and X . Thus, any assay that acts as a measure of the activity 
of one or more of these factors can potentially act as a tool to assess drug effects . The prothrombin time (PT) adjusted to an Interna-
tional Normalised Ratio (INR) is determined to offer the best practical solution in this regard . 
B & C . Control points for heparin, which exerts its effects via antithrombin (AT) . Low molecular weight heparins (LMWH; e .g ., Clexane 
and Fragmin) express primarily anti-Xa activity . Unfractionated heparin (UH) expresses primarily anti-thrombin (anti-IIa) activity . To 
a lesser extent, LMWH also expresses some anti-thrombin activity and UH also expresses some anti-Xa activity . The assays judged to 
best measure the relevant activity and drug effects in this system are the APTT and anti-Xa assays . The APTT is sensitive to UH and is 
thus used to monitor UH therapy . The APTT is relatively insensitive to LMWH, and thus this can only be monitored by the anti-Xa as-
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non-inferiority or superiority to alternate thera-
pies, typically the LMWH enoxaparin, 40 mg once 
daily for prevention of VTE or VKA for prevention 
of systemic embolism in patients with AF .
No monitoring required?
Although most of these novel anticoagulant 
agents have been developed on the premise of 
not requiring any monitoring, the reality is proving 
to be quite different . Overall, there will be many 
occasions in which clinicians will like to know 
whether or not an anticoagulant effect is evident: 
1) an unconscious patient admitted to hospital 
with trauma, bleeding or for urgent surgery – 
the presence of active anticoagulant may influ-
ence management or increase the risk of peri-
operative bleeding; 
2) a case of attempted suicide – has an overdose 
of anticoagulant drug been taken?; 
3) a case of thrombosis or hemorrhage while on 
anticoagulant therapy to help assess compli-
ance or therapy failure; 
4) when bridging from one anticoagulant to an-
other; 
5) for assessing compliance in select individuals; 
6) in patients with metabolic abnormalities (e .g ., 
those with impaired renal or liver function) or 
extreme body size; or
7) to establish whether co-medication effects are 
affecting drug efficacy . 
As specifically regards assessing compliance, the 
half life of most of the new oral anticoagulants is 
comprised between 10 and 14 hours, with antico-
agulant effects spanning from 24 to 36 hours . As 
such, compliance may be virtually assessed only 
within ~12 hours from ingestion of the last tablet . 
It is also noteworthy that test results may be highly 
different when the blood sample is collected 2 
hours after the last tablet intake (which roughly 
corresponds to the peak) as compared with 12 or 
24 hours afterwards in cases of twice or once daily 
intake, respectively .
However, as these agents have been developed 
and assessed in clinical trials without any monitor-
ing of anticoagulant effect, there are no standard-
ized or well established tests for their effective as-
sessment . As the new agents are either directed 
against FIIa or FXa, then tests that are sensitive to 
these agents are those most likely to be used for 
their laboratory assessment . 
Dabigatran etexilate
For Dabigatran, the standard PT assay is too insen-
sitive, and the APTT, although somewhat sensitive 
(increases in non-linear fashion), may underesti-
mate high levels (24,29-32) (Table 1) . This may pose 
a significant problem in terms of over-dosing risk 
assessment . As Dabigatran is an anti-thrombin 
agent, it has no effect on the anti-Xa assay . The 
ecarin clotting time (ECT) and TT are both sensi-
tive to Dabigatran (Figure 3), but the standard TT is 
oversensitive . Thus, the main contenders for rou-
tine use appear to be either the ECT or a modified 
(e .g ., ‘diluted’) TT, although a combination of as-
says may provide a better clue for the possible sce-
nario of Dabigatran overdosing . Interestingly, the 
manufacturer of Dabigatran (Boehringer Ingel-
heim) has recently published in-vitro studies (33) 
using a commercial dilute TT method called 
HEMOCLOT (HYPHEN BioMed, France), and thus 
indicating that the manufacturer itself recognizes 
the value of assessing for drug levels in select cir-
cumstances and specific clinical conditions . It is 
also interesting that Boehringer Ingelheim now 
appear to be favoring the HEMOCLOT assay for 
this purpose . Although it is possible to use in-
house derived (e .g ., ‘dilute’) TT method for assess-
ing Dabigatran, there is merit in having a stand-
ardized commercial assay to improve cross-labora-
tory concordance and harmonization .
The ECT, however, remains in contention . The ECT 
is a meizothrombin generation test that can gen-
erally be used to measure the activity of direct 
thrombin inhibitors (Figure 3) . Ecarin is a highly 
purified metalloprotease isolated from the venom 
of the saw-scaled viper Echis carinatus and a spe-
cific activator of prothrombin (34) . However, to 
date, there is no standard ECT methodology avail-
able . An alternative to the ECT is a commercially 
available echarin based chromogenic assay . 
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Table 1. A summary of laboratory tests used in monitoring/testing anticoagulant therapy/activity .
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Figure 3. Control points for new agents directed against thrombin (FIIa) and factor (F) Xa, and representation of testing by specific 
coagulation assays . These agents do not require antithrombin (AT) in order to exert their anticoagulant effects . 
A . Similar to LMWH, Rivaroxaban has anti-Xa activity and can therefore be monitored by an anti-Xa assay . Note, however, that the 
standard assay used to monitor LMWH is too sensitive to Rivaroxaban, and needs to be modified . Similar to UH, Dabigatran has anti-
IIa activity, and thus the TT is sensitive to Dabigatran . Note, however, that the standard TT assay is too sensitive to Dabigatran, and 
needs to be modified .
B . A representation of the ecarin clotting assay, likely to emerge as a useful test for the assessment of anti-thrombin (FIIa) agents such 
as Dabigatran . The assay is sensitive to the effects of such agents, is simple to perform, able to be adapted to and automated on most 
routine laboratory coagulation instruments, and also likely to be capable of standardisation . A chromogenic version is also available .
C . A representation of the (dilute) Russell Viper Venom Time (dRVVT) assay, currently under-investigated for any potential utility in as-
sessing the effects of Dabigatran and Rivaroxaban, but which may emerge as a useful test for such purpose .
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Rivaroxaban
Although the PT shows some linearity against Ri-
varoxaban concentrations with some (but not all) 
reagents (24,35-37), the INR system, developed for 
VKA therapy, is not recommended for assessing Ri-
varoxaban activity, as ISI and MNPT values devel-
oped for VKA use may not apply to this agent (Ta-
ble 1) . As Rivaroxaban is directed against FXa, it 
has no effect on the ECT or the TT . The APTT is also 
prolonged by Rivaroxaban in a dose dependent 
manner, and anti-FXa activity is also influenced by 
Rivaroxaban (35-37) . However, the standard anti-
Xa assay, as used for monitoring heparin, is too 
sensitive to Rivaroxaban, and thus a modified (or 
‘diluted’) assay is required for use in Rivaroxaban 
testing . Nevertheless, the anti-Xa assay remains 
the most likely contender for assessment of Rivar-
oxaban activity (Figure 3), although PT and APTT 
assays, perhaps in modified form, may also emerge 
as useful tests for this purpose . 
Can we use other laboratory tests to monitor these 
agents?
Other tests evaluated for sensitivity to these two 
agents, as well as many other agents in develop-
ment, include the dilute PT, the reptilase time, 
thrombin generation, thromboelastography, Hep-
Test (a clot based anti-Xa assay), the ‘prothrombi-
nase induced clotting time’ (PICT), the dilute Rus-
sell Viper Venom Time assay, and a chromogenic 
anti-FIIa assay (3,24,29-32,35-37) . The behaviour of 
some of these tests was as expected, and on other 
occasions appears paradoxical (e .g ., low doses of 
Rivaroxaban showed an unexpected shortening of 
the PICT), thus suggesting that some test refine-
ments would be necessary before such tests could 
be utilised for assessment of anticoagulant activity 
with these agents . 
Unlike the standard routine assays, some of these 
tests are unavailable (and likely to remain as such) 
to most laboratories, and therefore unlikely to be 
initiated for routine assessment of these agents . 
For example, the thrombin generation assay is af-
fected by both Dabigatran and Rivaroxaban (24), 
and may be useful not only for detecting over-co-
agulation, but also for monitoring anticoagulation 
reversal (38) . However, it is unlikely that many lab-
oratories could implement the thrombin genera-
tion assay in practice, as it cannot be performed 
using standard coagulation equipment .
One assay that appears to have been under-inves-
tigated in this arena is the dilute Russell’s viper 
venom time (dRVVT) assay, which is most com-
monly employed as the major test in the investiga-
tion of lupus anticoagulant (LA) (39,40) . The dRVVT 
is sensitive to effects of both FX/FXa and FII/FIIa, 
and thus represents an assay that could hold utili-
ty for assessing the effects of both Dabigatran and 
Rivaroxaban . Indeed, preliminary testing has 
shown the dRVVT to be more sensitive to the ac-
tivities of these agents than some other tests pre-
viously investigated (Figure 4) . Given that this test 
is commonly utilized by laboratories for LA investi-
gation (39,40), it should be more fully investigated 
for potential utility in other scenarios such as as-
sessing the new anticoagulants .
Standards
Although there are several tests that in theory 
could assess whether or not there is anticoagulant 
activity associated with many of the new anticoag-
ulants, standards for assay calibration have only 
recently become available, hampering progress 
with in-vitro testing and standardisation . In theory, 
Rivaroxaban obtained as a pharmacy supply could 
be used as a laboratory calibrator standard (i .e ., by 
spiking plasma samples), just like heparin obtained 
from a pharmacy supply is typically used as a 
standard/calibrator for anti-Xa testing in heparin 
monitoring applications . On the other hand, Dab-
igaran etexilate is a pro-drug, requiring in vivo 
conversion to an active compound for its activity, 
further complicating provision of an in vitro stand-
ard by which to effectively reflect its biological ac-
tivity in vivo . That is, Dabigaran etexilate itself can-
not be used as a standard (i .e ., by spiking plasma 
samples) in a laboratory testing process attempt-
ing to assess its ex-vivo activity . Moreover, given 
the clinical testing and subsequent marketing of 
these agents as ‘not requiring monitoring’, there 
has been resistance from the drug manufacturers 
to provide active drugs that could be used by lab-
oratory as assay standards, presumably since this 
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would reflect a position at odds with their drug 
‘no-monitoring required’ marketing strategy . 
However, this situation may be set to change, giv-
en the recent interesting and apparent shift from 
Boehringer Ingelheim, the manufacturer of Dab-
igaran etexilate (33) .
Future perspectives
The development of new anticoagulants that in 
theory do not require monitoring would predict 
the demise of the current anticoagulants (i .e ., hep-
arin and VKAs), and thus the potential ‘doom’ of 
routine coagulation tests, given that these tests 
are primarily used for this purpose . Indeed, even 
should ‘occasional testing’ be required for the new 
anticoagulants, the standard tests (PT/INR, APTT, 
TT) as currently performed in laboratories would 
not be suitable, due to poor sensitivity, over sensi-
tivity, and/or the lack of an optimal dose-response 
relationship . Since these routine tests reflect the 
‘core business’ of haemostasis testing, the obvious 
question arises of whether this marks the inevita-
















































































Figure 4. Comparative sensitivities of PT, APTT and dRVVT assays to Dabigatran and Rivaroxaban using data derived from the West-
mead laboratory . Reagents were respectively: Thromborel S (Siemens, Sydney Australia), TriniClot APTT HS (Tcoag, Bray, Ireland), 
STA®-Staclot® DRVV Confirm reagent (Stago, Sydney Australia) . Dabigatran and Rivaroxaban plasma standards as tested were from 
Hyphen BioMed (purchased from Haematex, Sydney Australia) . All testing was performed on a STA-R Evolution instrument (Stago, 
Sydney Australia) . 
A . Dabigatran concentration vs . clotting times . 
B . Rivaroxaban concentration vs . clotting times . 
C . Dabigatran concentration vs . clotting ratio (clotting time/baseline clotting time) . 
D . Rivaroxaban concentration vs . clotting ratio (clotting time/baseline clotting time) . 
Note the comparative dRVVT findings in each case . In particular, the dRVVT was sensitive to both anticoagulants and clotting ratios 
for dRVVT were reasonably linear and similar for Dabigatran and Rivaroxaban over the tested concentrations .
Favaloro EJ, Lippi G . Laboratory testing of anticoagulants
Biochemia Medica 2012;22(3):329-41 
  339
Our advice is don’t close up shop just yet . Despite 
the optimistic predictions about the superior clini-
cal utility of the new anticoagulants as antithrom-
botic agents, the existing anticoagulants (i .e ., 
VKAs, heparin/heparinoids) are likely to remain in 
use for some time to come (1,3,28) . The new anti-
coagulants appear from clinical trials to have a fa-
vorable safety profile . Nevertheless, the high spec-
ificity (i .e ., either anti-IIa or anti-Xa) of these agents 
would indicate limited utility for some applica-
tions . For example, these agents may not be able 
to replace the conventional anticoagulant drugs in 
polytherapeutic approaches (e .g ., management of 
coronary syndromes, thrombotic stroke, and ma-
lignancy-associated thrombosis) . The current lack 
of reversal or antidote for most agents also means 
general unsuitability for some ‘during surgery’ in-
dications such as on-pump coronary bypass, 
where heparin and anti-aggregant agents are still 
the cornerstone of therapy . Cost is another issue . 
Heparin and VKAs are cheap drugs compared to 
the new anticoagulants . Patients in developing 
countries as well as sections of the population in 
developed countries may remain on VKA therapy 
simply because of affordability, which is also linked 
to compliance . With the expense of the new drugs, 
some patients are tempted to skip or reduce dos-
es, with potentially devastating consequences, 
and so may be more safely managed on VKAs . 
Drug evaluation studies are also performed with se-
lected patient cohorts, in many respects ‘ideal’ pa-
tients, with many other subjects (‘non-ideal’ pa-
tients) excluded for various reasons (41,42) . Typically 
excluded are those patients with renal and liver dys-
functions, pregnant women, pediatric populations, 
individuals at extremes of body weight and individ-
uals with complex disease and multiple morbidities . 
Notably, there was a high exclusion rate in the clini-
cal trials evaluating both Dabigatran and Rivaroxa-
ban . However, when these drugs are eventually re-
leased and approved for selective indications in the 
real world, ‘non-ideal’ patients, including those ex-
cluded by clinical trial criteria, will also need to be 
managed by anticoagulation therapy . There has also 
been much recent publicity about adverse events 
including death whilst on the new agents, and pos-
sibly related to selection of inappropriate patients 
to treat (e .g ., renal dysfunction) . Naturally, the old 
anticoagulants are also not without significant risk 
of bleeding or other serious adverse outcomes, as 
previously highlighted . The future anticoagulation 
of patients with complex diseases is again worth 
raising here . Clinical trials that aim to include such 
patients will be delayed by drug developers, given 
the possibility of adverse comparative findings 
against the classical agents, and thus potential neg-
ative influence on approvals for other indications . 
Another interesting consideration is the potential 
role of anticoagulant therapy in modulating cancer 
spread, given the reported bidirectional relationship 
of cancer and haemostasis (43) . At the current time, 
heparins - especially LMWH - appear to provide the 
best potential option in this regard, believed due to 
their anti-thrombin activity which targets the pro-
tease-activated receptor (PAR) pathway, and thus, 
the potential role of the new anticoagulants in this 
area of treatment remains an academic point .
Conclusions
In summary, the new oral anticoagulants cannot 
entirely replace the classical anticoagulants (hepa-
rin and VKAs) . Therefore, these will remain key anti-
coagulants for the foreseeable future . As these will 
still require laboratory monitoring, the routine co-
agulation tests (PT/INR and APTT) will similarly re-
main a part of this foreseeable future as well . These 
tests will also still have value in assessing for hae-
mostasis related defects, potentially related to 
both bleeding and thrombosis (1,6,8,9,44,45) . 
Moreover, renal failure, liver dysfunction, extremes 
of body weight and even genetic polymorphisms 
may influence adsorption, clearance, metabolism 
and excretion of some of the new and emerging 
anticoagulants . Combined with the current lack of 
ideal anticoagulant antidotes, the need or clinical 
desire for laboratory testing (in lieu of ‘monitoring’) 
of the new anticoagulants is predictable . Addition-
al reasons for laboratory testing include to assess 
compliance or therapy failure (unexpected throm-
bosis or bleeding), to establish whether co-medi-
cation effects may be affecting drug efficacy, when 
bridging from one anticoagulant to another, and in 
unconscious patients (e .g ., trauma) undergoing 
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surgery . Accordingly, ‘routine’ laboratory testing of 
the new anticoagulants will also develop over time . 
Evaluations into which tests might be useful for 
monitoring these have started, with the diluted TT 
or ECT, and the chromogenic anti-Xa assays cur-
rently emerging as clear leaders for potential clini-
cal utility of Dabigatran and Rivaroxaban testing 
respectively . However, the ‘common’ tests, includ-
ing the PT and APTT, might be found to be suitable 
in time, albeit in modified form (e .g ., dilute PT) . A 
chromogenic anti-IIa or chromogenic ecarin assay 
would also be feasible contenders for assessment 
of Dabigatran, particularly for those laboratories al-
ready running a chromogenic anti-Xa assay . Finally, 
the dRVVT remains under-investigated but repre-
sents another potential opportunity, in theory per-
mitting dual assessment of both Dabigatran and 
Rivaroxaban . Nevertheless, performance of any of 
these assays for assessment of the anticoagulant 
effects of Dabigatran and Rivaroxaban in the ab-
sence of adequate standards and adequate test 
standardization would suggest current limited or 
questionable clinical utility . There will also be a 
clear need to develop appropriate quality control 
and external quality assurance processes for these 
tests when used in these settings, which is any-
thing but ancillary (46) . Specific laboratory coun-
seling on the most appropriate test to be ordered 
according to the drug being administered, as well 
as on the best way to interpret test results will also 
be necessary, at least for the initial period of utiliza-
tion of these novel anticoagulant agents (47,48) .
In conclusion, the ‘imminent demise’ of the routine 
coagulation laboratory, and of the PT/INR and APTT, 
appears a little premature . The future landscape will 
include a more varied test menu, tailored towards 
monitoring or testing of a broader group of antico-
agulants, including but not limited to heparin, VKAs, 
Dabigatran and Rivaroxaban . The classical five test 
(i .e ., PT/INR, APTT, TT, Fibrinogen and D-dimer) pan-
els used by many laboratories will also broaden . So, 
be prepared, instead, for a larger workload!
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